Accepted for/Published in: JMIR Bioinformatics and Biotechnology
Date Submitted: Jan 1, 2022
Date Accepted: Jul 4, 2022
"Immunoinformatics approach to develop a multi-epitope vaccine against SARS-CoV-2", Immunoinformatics study
ABSTRACT
Background:
Since the first appearance of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in China on December 2019, the world has now witnessed the emergence of the SARS-CoV-2 outbreak. Therefore, due to the high transmissibility rate of virus, there is an urgent need to design and develop vaccines against SARS-CoV-2 to prevent more cases affected by the virus.
Objective:
At the present study, a computational approach was proposed for vaccine design against the spike (S) protein, the key target for neutralizing antibody, and the envelope (E) protein of SARS-CoV-2, which contains a conserved sequence feature.
Methods:
In this study, we used previously reported epitopes of S protein which detected experimentally and we also identified a collection of predicted B-cell and MHC class II- restricted T-cell epitopes derived from E proteins that correspond identically to SARS-CoV-2 E protein.
Results:
The in-silico design of our potential vaccine against S and E proteins of SARS-CoV-2 demonstrated a high affinity to MHC class II molecules and effective results in immune response simulations.
Conclusions:
Based on the results of this study, the multi-epitope vaccine designed against S and E proteins of SARS-CoV-2 may be considered as a new, safe, and efficient approach against this pandemic.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.